mProX™ Human NTRK1 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NTRK1 is a gene that has been found to be involved in various types of tumors. In recent studies, NTRK1 fusions have been identified in soft tissue tumors, including sarcomas, and have shown good clinical response to targeted therapies such as larotrectinib. NTRK2, another gene in the NTRK family, has also been found to be involved in tumorigenesis, particularly in adult soft tissue tumors. The highly selective Trk tyrosine kinase inhibitors, including larotrectinib, have shown significant efficacy in treating tumors with NTRK fusions. NTRK2 fusions are less common compared to NTRK1 and NTRK3 fusions, but they have been identified in sarcomas with features reminiscent of solitary fibrous tumors, and patients have responded well to larotrectinib therapy. The identification of NTRK2 fusions in soft tissue tumors could significantly improve clinical outcomes through selective NTRK inhibitor therapy, especially in the first-line setting. Prompt RNA-based next-generation sequencing testing at initial diagnosis may benefit these patients. Additionally, NTRK fusions have been found in pediatric spindle cell tumors, where they have diagnostic relevance and can be targeted for therapy. Overall, the detection of NTRK1/2/3 gene fusions in tumor samples can be achieved through cost-efficient methods, providing an alternative to conventional analysis techniques.